ArticlePediatric blood & cancer2020

Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.

Amy E Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.